Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the
three
months ended in Mar. 2022, Genocea Biosciences spent$0.96 Mil on purchasing property, plant, equipment.
It gained$0.02 Mil from selling property, plant, and equipment.
It spent$0.00 Mil on purchasing business.
It gained$0.00 Mil from selling business.
It spent$0.00 Mil on purchasing investments.
It gained$0.00 Mil from selling investments.
It paid$0.00Mil for net Intangibles purchase and sale.
And it received$0.00 Mil from other investing activities.
In all, Genocea Biosciences
spent$0.94 Mil on investment activities in financial market and operating subsidiaries for the
three
months ended in Mar. 2022.
Genocea Biosciences Cash Flow from Investing Historical Data
The historical data trend for Genocea Biosciences's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Genocea Biosciences Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Cash Flow from Investing
34.91
-0.13
-1.09
-2.56
-3.21
Genocea Biosciences Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Cash Flow from Investing
-1.04
-0.71
-0.53
-0.92
-0.94
Genocea Biosciences Cash Flow from Investing Calculation
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Genocea Biosciences's Cash Flow from Investing for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genocea Biosciences (OTCPK:GNCAQ) Cash Flow from Investing Explanation
Genocea Biosciences's purchase of property, plant, equipment for the
three
months ended in Mar. 2022 was $-0.96 Mil. It means Genocea Biosciences spent $0.96 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
Genocea Biosciences's sale of property, plant, equipment for the
three
months ended in Mar. 2022 was $0.02 Mil. It means Genocea Biosciences gained $0.02 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Genocea Biosciences's purchase of business for the
three
months ended in Mar. 2022 was $0.00 Mil. It means Genocea Biosciences spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Genocea Biosciences's sale of business for the
three
months ended in Mar. 2022 was $0.00 Mil. It means Genocea Biosciences gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Genocea Biosciences's purchase of investment for the
three
months ended in Mar. 2022 was $0.00 Mil. It means Genocea Biosciences spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Genocea Biosciences's sale of investment for the
three
months ended in Mar. 2022 was $0.00 Mil. It means Genocea Biosciences gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Genocea Biosciences's net Intangibles purchase and sale for the
three
months ended in Mar. 2022 was $0.00 Mil.
It means Genocea Biosciences paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Genocea Biosciences's cash from discontinued investing activities for the
three
months ended in Mar. 2022 was 0.00 Mil.
It means Genocea Biosciences paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Genocea Biosciences's cash from other investing activities for the
three
months ended in Mar. 2022 was $0.00 Mil.
It means Genocea Biosciences received $0.00 Mil from other investing activities.
Genocea Biosciences Cash Flow from Investing Related Terms
Thank you for viewing the detailed overview of Genocea Biosciences's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Genocea Biosciences (Genocea Biosciences) Business Description
Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GNCAQ has been successfully added to your 